

ASX Release

Anatara Board changes

- Dr. Jane Ryan retires as a non-executive director
- Mr. John Michailidis appointed as executive director

Adelaide, 2 October 2023: Anatara Lifesciences (ASX: ANR or “the Company”), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, announces that Dr Jane Ryan has retired as Non-Executive Director effective immediately. Mr John Michailidis has simultaneously been appointed as an Executive Director and remains in the role of COO (Chief Operating Officer).

Anatara’s Executive Chair, Dr David Brookes said that “On behalf of the Company we wish Jane the very best with her many endeavours and thank her for years of service. John brings significant governance experience and has been working closely with the Board since his management role appointment in June 2022. The current Board structure is consistent with Company’s stated intention to bring other opportunities in while commercialising the GaRP technology and other current assets. The Stage 1 analysis of the GaRP IBS trial was extremely encouraging as a potential product with broad gastrointestinal health indications and as a long-term portfolio asset.” (Please refer ASX:ANR announcement 28 September 2023)

The Board now consists of Dr David Brookes as Executive Chair, Mr Nick Haslam as Non-Executive Director and Chair of the Audit and Risk Committee, and John Michailidis whose bio follows:

John has more than 30 years of pharmaceutical experience. He is a driven leader in business transformation, entrepreneurship, translation and commercialisation, and has experience and expertise in a broad range of areas including strategic planning, organisational growth and business development.

John is currently the Chief Operating Officer of Anatara and the Managing Director of JEM Pharmaceuticals Pty Ltd. He has gained experience in a number of senior and executive positions throughout his career, including as Non-Executive Director of Factor Therapeutics Pty Ltd and Australian Diabetes Educators Association, the Chair of Access Community Health, Managing Director of Teva Pharma Australia Pty Ltd and Business Director and Global Head of the Nephrology/Oncology Franchise for F. Hoffman La Roche. John also has CEO experience with growth-stage pharmaceutical companies including Orphan Australia Pty Ltd, Avipep Pty Ltd and Roche Korea Ltd.

John holds a Bachelor of Science (Honours) from LaTrobe University, an Executive MBA from Harvard University, a Diploma in Education from Melbourne University, and he is a member of the Australian Institute of Company Directors.



For more information please contact:

Dr. David Brookes

Chair, Anatara Lifesciences Ltd

+61 (0) 411 712 579

dbrookes@anatara.com

Dirk van Dissel

Candour Advisory – Investor Relations

+61 (0) 408 326 367

dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited
Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email info@anatara.com | Website anataralifesciences.com

